{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:39:16Z","timestamp":1760747956002,"version":"build-2065373602"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.canlet.2024.217382","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T02:36:50Z","timestamp":1733279810000},"page":"217382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Construction and characterization of a novel secreted MsC-CAR-T cell in solid tumors"],"prefix":"10.1016","volume":"611","author":[{"given":"Yuan","family":"Mao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2907-5870","authenticated-orcid":false,"given":"Yiting","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daixun","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenqing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuirong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.canlet.2024.217382_bib1","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","article-title":"Engineered cellular immunotherapies in cancer and beyond","volume":"28","author":"Finck","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.217382_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216318","article-title":"The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells","volume":"569","author":"Lin","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217382_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216032","article-title":"5-ALA mediated photodynamic therapy with combined treatment improves anti-tumor efficacy of immunotherapy through boosting immunogenic cell death","volume":"554","author":"Sun","year":"2023","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.canlet.2024.217382_bib4","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (Atezolizumab) in advanced solid tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2024.217382_bib5","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","article-title":"Design and efficacy of a monovalent bispecific PD-1\/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells","volume":"11","author":"Dovedi","year":"2021","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.canlet.2024.217382_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201908961","article-title":"Inhibition of immunosuppressive tumors by polymer-assisted inductions of immunogenic cell death and multivalent PD-L1 crosslinking","volume":"30","author":"Li","year":"2020","journal-title":"Adv. Funct. Mater."},{"issue":"7","key":"10.1016\/j.canlet.2024.217382_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.canlet.2024.217382_bib8","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.21.01845","article-title":"Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies","volume":"40","author":"Passaro","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2024.217382_bib9","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200377","article-title":"Adoptive cell therapy: living drugs against cancer","volume":"217","author":"Laskowski","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.217382_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215949","article-title":"BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"553","author":"Yang","year":"2023","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.canlet.2024.217382_bib11","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"issue":"15","key":"10.1016\/j.canlet.2024.217382_bib12","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1158\/1078-0432.CCR-23-3495","article-title":"Arming v\u03b42 T cells with chimeric antigen receptors to combat cancer","volume":"30","author":"Thomas","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2024.217382_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13045-019-0793-7","article-title":"MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells","volume":"12","author":"Mao","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.217382_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cellimm.2018.04.007","article-title":"Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer","volume":"329","author":"He","year":"2018","journal-title":"Cell. Immunol."},{"issue":"9","key":"10.1016\/j.canlet.2024.217382_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-016-0285-y","article-title":"Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level","volume":"20","author":"Song","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217382_bib16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.canlet.2024.217382_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"16","key":"10.1016\/j.canlet.2024.217382_bib18","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1158\/1078-0432.CCR-17-1788","article-title":"Aberrant Lck signal via CD28 costimulation augments antigen-specific functionality and tumor control by redirected T cells with PD-1 blockade in humanized mice","volume":"24","author":"Gulati","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.canlet.2024.217382_bib19","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/cas.14169","article-title":"Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells","volume":"110","author":"Nakajima","year":"2019","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.canlet.2024.217382_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"13","key":"10.1016\/j.canlet.2024.217382_bib21","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.7150\/ijbs.60782","article-title":"CD47\/SIRPalpha pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.canlet.2024.217382_bib22","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1550619","article-title":"Anticancer effects of anti-CD47 immunotherapy in vivo","volume":"8","author":"Iribarren","year":"2019","journal-title":"OncoImmunology"},{"issue":"10","key":"10.1016\/j.canlet.2024.217382_bib23","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.canlet.2024.217382_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13402-019-00469-5","article-title":"CD47: role in the immune system and application to cancer therapy","volume":"43","author":"Hayat","year":"2020","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.canlet.2024.217382_bib25","article-title":"Single-cell RNA sequencing unravels distinct tumor microenvironment of different components of lung adenocarcinoma featured as mixed ground-glass opacity","volume":"13","author":"He","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.canlet.2024.217382_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003737","article-title":"Delivery of CD47 blocker SIRPalpha-Fc by CAR-T cells enhances antitumor efficacy","volume":"10","author":"Chen","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2024.217382_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/2326-6066.CIR-16-0398","article-title":"Targeting CD47 and autophagy elicited enhanced antitumor effects in non-small cell lung cancer","volume":"5","author":"Zhang","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.canlet.2024.217382_bib28","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s40425-019-0812-9","article-title":"Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"22","key":"10.1016\/j.canlet.2024.217382_bib29","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1182\/blood.2021013901","article-title":"Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression","volume":"139","author":"Cao","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.canlet.2024.217382_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246229","article-title":"Cancer therapy targeting CD47\/SIRPalpha","volume":"13","author":"Dizman","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.217382_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106269","article-title":"A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mphi polarization in TME","volume":"181","author":"Xiao","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2024.217382_bib32","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3389\/fpls.2018.01379","article-title":"An effective way of producing fully assembled antibody in transgenic tobacco plants by linking heavy and light chains via a self-cleaving 2A peptide","volume":"9","author":"Lin","year":"2018","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.canlet.2024.217382_bib33","article-title":"Bispecific c-met\/PD-L1 CAR-T cells have enhanced therapeutic effects on hepatocellular carcinoma","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217382_bib34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/gt.2017.3","article-title":"Balanced secretion of anti-CEA x anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity","volume":"24","author":"Molgaard","year":"2017","journal-title":"Gene Ther."},{"issue":"8","key":"10.1016\/j.canlet.2024.217382_bib35","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2174\/1568009622666220407111013","article-title":"TROP2 down-regulated DSG2 to promote gastric cancer cell invasion and migration by EGFR\/AKT and DSG2\/PG\/beta-Catenin pathways","volume":"22","author":"Yang","year":"2022","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.canlet.2024.217382_bib36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3389\/fonc.2019.00717","article-title":"High-affinity human anti-c-met IgG conjugated to oxaliplatin as targeted chemotherapy for hepatocellular carcinoma","volume":"9","author":"Ma","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.217382_bib37","doi-asserted-by":"crossref","first-page":"9341","DOI":"10.2147\/OTT.S221040","article-title":"CD137 Co-stimulation improves the antitumor effect of LMP1-specific chimeric antigen receptor T cells in vitro and in vivo","volume":"12","author":"Tang","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"5","key":"10.1016\/j.canlet.2024.217382_bib38","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ijc.28451","article-title":"A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo","volume":"134","author":"Lin","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2024.217382_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109420","article-title":"A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo","volume":"119","author":"Yin","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.canlet.2024.217382_bib40","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/biof.1498","article-title":"ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K\/Akt\/mTOR signaling pathway","volume":"45","author":"Mao","year":"2019","journal-title":"Biofactors"},{"key":"10.1016\/j.canlet.2024.217382_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106656","article-title":"Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma","volume":"188","author":"Peng","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.canlet.2024.217382_bib42","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.pathol.2016.08.001","article-title":"LAMP1 expression is associated with malignant behaviours and predicts unfavourable prognosis in laryngeal squamous cell carcinoma","volume":"48","author":"Lu","year":"2016","journal-title":"Pathology"},{"issue":"6","key":"10.1016\/j.canlet.2024.217382_bib43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/ejh.13851","article-title":"CAR-T cell therapy for patients with hematological malignancies. A systematic review","volume":"109","author":"Pasqui","year":"2022","journal-title":"Eur. J. Haematol."},{"issue":"20","key":"10.1016\/j.canlet.2024.217382_bib44","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood.2022017015","article-title":"Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL","volume":"140","author":"Rejeski","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.canlet.2024.217382_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"579","key":"10.1016\/j.canlet.2024.217382_bib46","article-title":"CTRP6 protects against ferroptosis to drive lung cancer progression and metastasis by destabilizing SOCS2 and augmenting the xCT\/GPX4 pathway","volume":"28","author":"Cai","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217382_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216368","article-title":"SEM1 promotes tumor progression of glioblastoma via activating the akt signaling pathway","volume":"577","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2024.217382_bib48","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.217382_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216182","article-title":"Immune-checkpoint inhibitor resistance in cancer treatment: current progress and future directions","volume":"562","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217382_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106036","article-title":"Improving the ability of CAR-T cells to hit solid tumors: challenges and strategies","volume":"175","author":"Zhang","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"623","key":"10.1016\/j.canlet.2024.217382_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.canlet.2024.217382_bib52","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2024.217382_bib53","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3389\/fcell.2020.00803","article-title":"Augmenting the effectiveness of CAR-T cells by enhanced self-delivery of PD-1-neutralizing scFv","volume":"8","author":"Ping","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217382_bib54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol. Rev."},{"issue":"8016","key":"10.1016\/j.canlet.2024.217382_bib55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2024.217382_bib56","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","article-title":"Targeting CD47 for cancer immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.217382_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110255","article-title":"The CD47-SIRPalpha axis is a promising target for cancer immunotherapies","volume":"120","author":"Hao","year":"2023","journal-title":"Int. Immunopharm."},{"issue":"12","key":"10.1016\/j.canlet.2024.217382_bib58","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-Human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217382_bib59","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4049\/jimmunol.2001019","article-title":"Novel SIRPalpha antibodies that induce single-agent phagocytosis of tumor cells while preserving T cells","volume":"206","author":"Andrejeva","year":"2021","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217382_bib60","doi-asserted-by":"crossref","first-page":"148","DOI":"10.7150\/thno.79367","article-title":"Blockade of dual immune checkpoint inhibitory signals with a CD47\/PD-L1 bispecific antibody for cancer treatment","volume":"13","author":"Wang","year":"2023","journal-title":"Theranostics"},{"issue":"24","key":"10.1016\/j.canlet.2024.217382_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202002852","article-title":"A rationally designed ICAM1 antibody drug conjugate for pancreatic cancer","volume":"7","author":"Huang","year":"2020","journal-title":"Adv. Sci."},{"issue":"3","key":"10.1016\/j.canlet.2024.217382_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202001493","article-title":"Sacrificial synthesis of supported Ru single atoms and clusters on N-doped carbon derived from covalent triazine frameworks: a charge modulation approach","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv. Sci."},{"issue":"3","key":"10.1016\/j.canlet.2024.217382_bib63","first-page":"216","article-title":"A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies","volume":"5","author":"Wang","year":"2022","journal-title":"Antib Ther"},{"issue":"1","key":"10.1016\/j.canlet.2024.217382_bib64","first-page":"45","article-title":"Optimization of therapeutic antibodies","volume":"4","author":"Wang","year":"2021","journal-title":"Antib Ther"},{"key":"10.1016\/j.canlet.2024.217382_bib65","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.omto.2021.01.002","article-title":"Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer","volume":"20","author":"Shu","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.canlet.2024.217382_bib66","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5575260","article-title":"Third-generation anti-CD47-specific CAR-T cells effectively kill cancer cells and reduce the genes expression in lung cancer cell metastasis","volume":"2021","author":"La","year":"2021","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.canlet.2024.217382_bib67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12951-024-02512-6","article-title":"BCMA\/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma","volume":"22","author":"Lu","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217382_bib68","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00262-017-2089-5","article-title":"Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor","volume":"67","author":"Zuo","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.canlet.2024.217382_bib69","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1158\/2326-6066.CIR-18-0874","article-title":"An improved patient-derived xenograft humanized mouse model for evaluation of lung cancer immune responses","volume":"7","author":"Meraz","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"8","key":"10.1016\/j.canlet.2024.217382_bib70","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2024.217382_bib71","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omto.2023.07.003","article-title":"Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells","volume":"30","author":"Magnani","year":"2023","journal-title":"Mol Ther Oncolytics"},{"issue":"10","key":"10.1016\/j.canlet.2024.217382_bib72","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the immunosuppressive tumor microenvironment of hodgkin lymphoma using chimeric antigen receptor T cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov."},{"issue":"564","key":"10.1016\/j.canlet.2024.217382_bib73","article-title":"Reprogramming of TAMs via the STAT3\/CD47-SIRP\u03b1 axis promotes acquired resistance to EGFR-TKIs in lung cancer","volume":"28","author":"Lu","year":"2023","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.canlet.2024.217382_bib74","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1007\/s00432-022-04292-8","article-title":"A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade","volume":"149","author":"Ozaniak","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217382_bib75","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-022-01597-7","article-title":"Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4\/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer","volume":"21","author":"Heidegger","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2024.217382_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216727","article-title":"Glutamine inhibition combined with CD47 blockade enhances radiotherapy-induced ferroptosis in head and neck squamous cell carcinoma","volume":"588","author":"Song","year":"2024","journal-title":"Cancer Lett."},{"issue":"Pt A","key":"10.1016\/j.canlet.2024.217382_bib77","article-title":"CAR cell design strategies in solid tumors","volume":"113","author":"Wang","year":"2022","journal-title":"Int. Immunopharm."},{"issue":"10","key":"10.1016\/j.canlet.2024.217382_bib78","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jtct.2022.06.025","article-title":"The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells","volume":"28","author":"Moscarelli","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.canlet.2024.217382_bib79","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.ymthe.2024.04.005","article-title":"Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.canlet.2024.217382_bib80","doi-asserted-by":"crossref","first-page":"465","DOI":"10.17305\/bb.2023.9675","article-title":"CAR-macrophage versus CAR-T for solid tumors: the race between a rising star and a superstar","volume":"24","author":"Chen","year":"2024","journal-title":"Biomol Biomed"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524007778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524007778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T22:57:42Z","timestamp":1760741862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524007778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":80,"alternative-id":["S0304383524007778"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217382","relation":{},"ISSN":["0304-3835"],"issn-type":[{"type":"print","value":"0304-3835"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Construction and characterization of a novel secreted MsC-CAR-T cell in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217382"}}